InvestorsHub Logo
Followers 9
Posts 238
Boards Moderated 0
Alias Born 07/14/2011

Re: None

Wednesday, 07/30/2014 10:56:52 AM

Wednesday, July 30, 2014 10:56:52 AM

Post# of 40490
Immunotherapies and Vaccine Summit (August 11 -14)
http://www.imvacs.com

Hopefully we get a little more of the phase II data at this conference.

Tuesday August 12th
4:15 Engineering Cancer Immunotherapy One (DNA) Sequence at
a Time Mark Bagarazzi, M.D., CMO, Inovio Pharmaceuticals
Inovio is developing cancer immunotherapeutics by targeting both viral oncogenes (HPV E6, E7) as well as self proteins associated with cancer progression and metastases (PSA, PSMA, hTERT). Our common approach involves enhancing the delivery of optimized DNA sequences with the use of our proprietary in vivo electroporation system. We will share both preclinical and clinical data regarding several cancer indications.

WEDNESDAY, AUGUST 13

PREDICTING & ENHANCING HUMAN RESPONSE
8:25 Chairperson’s Opening Remarks
Mark Bagarazzi, M.D., CMO, Inovio Pharmaceuticals
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News